SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

SMS Pharmaceuticals - Quaterly Results

08 Nov 2023 Evaluate
The quarter ended September 2023 witnessed marginal change in the total revenue. The figure for the mentioned quarter is pegged at Rs. 1666.44 millions.Net Profit witnessed a 1428.81% growth almost the double from Rs. 7.88 millions to Rs. 120.47  millions  of same quarter last year.Operating Profit saw a handsome growth to 286.32 millions from 142.31 millions in the quarter ended September 2023.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202309 202209 % Var 202309 202209 % Var 202303 202203 % Var
Sales 1666.44 1594.33 4.52 3019.83 2238.22 34.92 5220.51 5198.74 0.42
Other Income 8.10 6.14 31.92 13.23 14.15 -6.50 48.86 51.98 -6.00
PBIDT 286.32 142.31 101.19 558.03 146.08 282.00 595.90 1196.83 -50.21
Interest 55.72 52.43 6.28 118.95 100.93 17.85 219.15 188.75 16.11
PBDT 230.60 89.88 156.56 439.08 45.15 872.49 376.75 1008.08 -62.63
Depreciation 79.00 80.92 -2.37 155.91 160.26 -2.71 321.25 321.52 -0.08
PBT 151.60 8.96 1591.96 283.17 -115.11 -346.00 55.50 686.56 -91.92
TAX 31.13 1.08 2782.41 69.87 -24.94 -380.15 14.65 6.18 137.06
Deferred Tax 0.13 1.08 -87.96 4.87 -24.94 -119.53 14.69 -143.02 -110.27
PAT 120.47 7.88 1428.81 213.30 -90.17 -336.55 40.85 680.38 -94.00
Equity 84.65 84.65 0.00 84.65 84.65 0.00 84.65 84.65 0.00
PBIDTM(%) 17.18 8.93 92.49 18.48 6.53 183.13 11.41 23.02 -50.42

SMS Pharmaceuticals Share Price

427.60 3.45 (0.81%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×